Thyroid microcancer study: surgery, heat ablation, or just watching?
NCT ID NCT07249125
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 1,630 people with a small, low-risk thyroid cancer to compare three management options: surgery, heat ablation (a minimally invasive procedure), or active surveillance (monitoring without immediate treatment). The goal is to see which approach offers the best safety and quality of life over 10 years. Participants choose their treatment with their doctor, and researchers track cancer spread and patient well-being.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,630 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Dec 2025
An estimate. Start dates often move.
- Expected to finish
-
Jun 2039
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients diagnosed with low-risk papillary thyroid microcarcinoma (maximum diameter ≤1 cm), with no evidence of extrathyroidal extension, lymph node metastasis, or distant metastasis, who choose one of three management strategies: surgical resection, thermal ablation, or active surveillance.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * A single papillary thyroid carcinoma (PTC) lesion with a maximum diameter ≤ 1 cm confirmed by imaging. * No evidence of extrathyroidal extension on imaging studies. * No clinical or radiologic evidence of cervical lymph node metastasis. * No evidence of distant metastasis. * Histopathological confirmation of papillary thyroid carcinoma. * The patient has provided written informed consent and agrees to select one of the predefined management strategies (surgical resection, thermal ablation, or active surveillance). Exclusion Criteria: * Ultrasound-confirmed tumor with a maximum diameter \> 1 cm. * Imaging findings (ultrasound/CT/MRI) suggestive of extrathyroidal extension. * Tumor located adjacent to critical structures (e.g., trachea, esophagus, or recurrent laryngeal nerve) with possible invasion risk. * History of thyroidectomy, radiofrequency/microwave/laser ablation, or radioactive iodine therapy. * Failure to provide written informed consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Papillary thyroid microcarcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Xijing hospital
Xi'an, Shaanxi, 710032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.